Edition:
United States

Agios Pharmaceuticals Inc (AGIO.O)

AGIO.O on Nasdaq

58.21USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$58.21
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
667,755
52-wk High
$69.67
52-wk Low
$33.50

AGIO.O

Chart for AGIO.O

About

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and... (more)

Overall

Beta: 2.14
Market Cap(Mil.): $2,710.79
Shares Outstanding(Mil.): 42.01
Dividend: --
Yield (%): --

Financials

  AGIO.O Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -4.80 -- --
ROI: -36.77 -1.09 14.95
ROE: -47.00 -2.39 16.29

BRIEF-Agios provides early-stage data on AG-120 in glioma, chondrosarcoma patients

* Agios announces phase 1 data from dose expansion cohorts of AG-120 in patients with IDH1 mutant positive glioma and chondrosarcoma Source text for Eikon: Further company coverage:

Nov 18 2016

BRIEF-Agios posts Q3 shr loss $1.63

* Agios Pharmaceuticals inc - now expects to end 2016 with more than $550 million of cash, cash equivalents and marketable securities

Nov 03 2016

BRIEF-Agios Pharma says Celgene expects to submit NDA to U.S. FDA for enasidenib

* Celgene corporation expects to submit a new drug application to U.S. FDA for Enasidenib (ag-221)

Sep 07 2016

BRIEF-Agios Pharmaceuticals appoints Andrew Hirsch as chief financial officer

* Glenn Goddard, senior vice president of finance, will be leaving company at end of September to pursue other opportunities

Aug 16 2016

BRIEF-Agios Pharmaceuticals reports qtrly loss per share $1.47

* Collaboration revenue was $7.0 million for quarter ended June 30, 2016, compared to $13.2 million for comparable period in 2015

Aug 04 2016

BRIEF-Agios Pharma reports initial data from phase 1 study of AG-519 in healthy volunteers

* Agios reports initial data from phase 1 study of ag-519 in healthy volunteers Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 09 2016

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $32.14 --
Novartis AG (NOVN.S) CHF69.30 -0.95
Roche Holding Ltd. (ROG.S) CHF223.20 -3.50
Roche Holding Ltd. (RO.S) CHF226.00 -4.10
Sanofi SA (SASY.PA) €74.94 -1.17
AstraZeneca plc (AZN.L) 4,091.00p -58.50
GlaxoSmithKline plc (GSK.L) 1,465.50p -30.00
Eli Lilly and Co (LLY.N) $67.12 --
Shire PLC (SHP.L) 4,597.00p -63.00
Shire PLC (3159084.L) -- --

Earnings vs. Estimates